Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma × Blood Specimen Collection × Clear all

Phase

Phase NA 11 Phase 4 2 Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Papillomavirus Infections 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Osteoporosis 1 Melanoma 1 Infertility, Female 1 Elective Surgery for Any Digestive Cancer 1 Crohn Disease 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Ductal Infiltrating Metastatic 1 Barrett Esophagus 1 Airway Obstruction 1

Interventions

Dacarbazine 22 Nivolumab 20 pembrolizumab 15 Ipilimumab 15 Interferon-alpha 10 trametinib 7 aldesleukin 7 dabrafenib 6 Vemurafenib 6 Temozolomide 6 Introns 6 Interferon alpha-2 6 Interleukin-2 5 Cisplatin 5 Radiotherapy 4 Chemotherapy, Adjuvant 4 cobimetinib 3 cemiplimab 3 binimetinib 3 Vinblastine 3 Specimen Handling 3 Sodium Chloride 3 Radiosurgery 3 Paclitaxel 3 Opdualag 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 CTLA-4 Antigen 3 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2 spartalizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02278887 2025-03-10

TIL

The Netherlands Cancer Institute

Phase 3 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡